Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
MWN-AI** Summary
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on precision dermatology, has announced the adjournment of its Special Meeting, originally scheduled for February 6, 2026, due to a lack of quorum. The meeting will reconvene on March 6, 2026, at 11:00 a.m. Eastern Time in a virtual format. The purpose of the adjournment is to solicit additional votes on proposals outlined in the company’s definitive proxy statement submitted to the SEC on January 2, 2026.
A quorum, necessary for proceeding with the meeting, was not met as only approximately 13% of the shares entitled to vote were represented, which fell short of the required 33 1/3%. The forthcoming Reconvened Special Meeting will address two main proposals: the first focuses on approving a significant share issuance related to a Securities Purchase Agreement with Alumni Capital LP, and the second is an optional proposal to adjourn the meeting if further votes are needed.
Azitra encourages its eligible stockholders, recorded as of January 2, 2026, to vote. Those who have previously submitted their votes need not take further action unless they wish to change their selection. Voting can be performed by mail, over the Internet, or by telephone, with a deadline set for 10:59 a.m. on March 6, 2026.
Currently, Azitra’s lead program, ATR-12, targets Netherton syndrome, a rare and serious skin disease. Their second program, ATR-04, aims to treat skin reactions from EGFR inhibitors. For detailed information, stakeholders can access the company’s filings through the SEC or visit Azitra’s investor relations website.
MWN-AI** Analysis
Azitra, Inc. (NYSE American: AZTR) recently announced the adjournment of its Special Meeting due to a lack of quorum, a critical step that signals the need for investor engagement and support ahead of the upcoming reconvened meeting scheduled for March 6, 2026. This delay highlights an essential moment for shareholders to reassess their investment strategies in the context of the company’s future trajectory.
The primary proposal under consideration—approval for the issuance of over 19.99% of common stock related to a securities purchase agreement—could significantly dilute existing shareholders. However, it is crucial to view this proposed fundraising as an opportunity for Azitra to bolster its financial position to fuel its clinical programs, particularly the promising ATR-12 and ATR-04 therapies.
From a market perspective, investors should approach Azitra with cautious optimism. The company's innovative focus on precision dermatology, particularly its work on treatments for conditions like Netherton syndrome, addresses urgent medical needs and positions Azitra well within a specific niche of the biopharmaceutical landscape. The fast-track designation by the FDA for ATR-04 demonstrates market potential. If shareholders support the proposals in March, this could unlock capital necessary for advancing critical clinical trials, potentially leading to significant value appreciation in the long term.
That said, the low turnout for the initial meeting indicates possible investor apathy or uncertainty. It's advisable for existing shareholders or potential investors to educate themselves on Azitra’s strategic direction and initiatives. Engaging actively with the upcoming reconvened meeting, whether through proxy voting or direct participation, will not only influence immediate outcomes but also demonstrate shareholders' commitment to growth-oriented funding strategies.
Investors are encouraged to keep abreast of developments and potential market reactions as Azitra navigates this crucial juncture. Understanding the implications of stock dilution versus potential growth will be essential in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the "SEC") on January 2, 2026 (the "Special Meeting Proxy Statement") because a quorum was not present at the Special Meeting.
A quorum would have been present if shares representing 33 1/3% of the common stock outstanding and entitled to vote were present at the Special Meeting virtually or represented by proxy. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 13% of the outstanding shares of stock entitled to vote, so a quorum did not exist.
Adjournment of Special Meeting
The Reconvened Special Meeting will be on March 6, 2026, at 11:00 a.m. Eastern Time and will continue to be held in a virtual format. Stockholders will be able to listen and participate in the virtual special meeting, as well as vote and submit questions during the live webcast of the meeting by visiting www.proxydocs.com/AZTR and entering the control number included in their proxy card. The proposals at the Reconvened Special Meeting will be the same as those at the Special Meeting:
- Proposal One: Approval, for purposes of complying with NYSE American Company Guide Section 713(a) and Section 713(b), of the issuance of more than 19.99% of our issued and outstanding shares of common stock, comprised of shares of common stock underlying warrants, pursuant to the Securities Purchase Agreement with Alumni Capital LP, dated November 24, 2025 (the "Purchase Agreement").
- Proposal Two: To adjourn the Special Meeting, if necessary, to solicit additional proxies if there are insufficient votes in favor of the foregoing proposal.
Azitra encourages eligible stockholders as of the record date of January 2, 2026, who have not yet voted their shares on the meeting proposals, or are uncertain if their shares have been voted on, to contact their broker or bank to vote their shares. The Board of Directors and management of the Company request that these stockholders consider and vote their proxies as soon as possible on the meeting proposals, but no later than March 6, 2026, at 10:59 a.m. Eastern Time.
Stockholders who have previously submitted their proxy and who do not want to change their vote need not take any action.
As described in the Special Meeting Proxy Statement, stockholders may use one of the following simple methods to, prior to the Adjourned Special meeting, vote their shares, or change their previously submitted vote, no later than March 6, 2026, at 10:59 a.m. Eastern Time with respect to the proposals:
- By mail. Complete and mail the proxy card in the postage prepaid envelope. If you return your signed proxy card to us before the Reconvened Special Meeting, we will vote your shares as you direct. If you sign the proxy card but do not specify how you want your eligible shares voted, they will be voted as recommended by our Board.
- Over the Internet. To submit a proxy to vote your shares through the Internet, go to www.proxypush.com/AZTR to complete an electronic proxy card. You will be asked to provide the control number from the proxy card delivered to you.
- By telephone. To submit a proxy to vote your shares telephonically, please call the toll-free number listed on your proxy card and follow the instructions provided.
Votes must be received by 10:59 a.m. Eastern Time on March 6, 2026, to be counted. After this time, votes can only be cast during the Reconvened Special Meeting on March 6, 2026, at 11:00 a.m. Eastern Time at www.proxydocs.com/AZTR.
About Azitra
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit https://azitrainc.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as "believe," "can," "could," "design," "estimate," "expect," "intend," "may," "might," "objective," "plan" "potential," "predict," "should," "will," "would," or the negative of these terms and similar expressions intended to identify forward-looking statements. These forward-looking statements include statements related to the meeting proposals, the timing and the outcome of the Reconvened Special Meeting, matters described above, the parties' expectations and related matters. Azitra cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in, or implied by, these forward-looking statements, including, but not limited to, the timing of the Reconvened Special Meeting. These and other risks and uncertainties are described more fully in the sections titled "Risk Factors" and "Cautionary Notice" in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed with the SEC. Forward-looking statements reflect the Company's analysis only on their stated date, and Azitra undertakes no obligation to update or revise these statements except as may be required by law.
Additional Information and Where to Find It
In connection with the solicitation of proxies, on January 2, 2026, Azitra filed the Special Meeting Proxy Statement with the SEC with respect to the Special Meeting. Promptly after filing the Special Meeting Proxy Statement with the SEC, Azitra mailed the Special Meeting Proxy Statement and a proxy card to each stockholder entitled to vote at the Special Meeting to consider the proposals. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT TRANSCODE HAS FILED OR WILL FILE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by Azitra with the SEC in connection with the proposals at the SEC's website (http://www.sec.gov) or at the Company's investor relations website (https://ir.azitrainc.com/financial-information/sec-filings). The information provided on, or accessible through, our website is not part of this communication, and therefore is not incorporated herein by reference.
Contact
Norman Staskey
Chief Financial Officer
staskey@azitrainc.com
Investor Relations
Tiberend Strategic Advisors, Inc.
Jon Nugent
205-566-3026
jnugent@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
646-577-8520
cmcdonald@tiberend.com
SOURCE Azitra, Inc.
FAQ**
Why did Azitra Inc AZTR fail to achieve a quorum at the Special Meeting held on February 6, 2026, and what steps is the company taking to encourage stockholders to participate in the Reconvened Special Meeting?
Can you provide details on the significance of Proposal One involving the potential issuance of more than 19.99% of Azitra Inc AZTR's outstanding shares under the Securities Purchase Agreement with Alumni Capital LP?
What are the potential implications for Azitra Inc AZTR's stock if stockholders do not approve the proposals at the Reconvened Special Meeting scheduled for March 6, 2026?
How are Azitra Inc AZTR's ongoing clinical programs, such as ATR-12 and ATR-0expected to be impacted by the outcome of the Reconvened Special Meeting and the decisions made by stockholders?
**MWN-AI FAQ is based on asking OpenAI questions about Azitra Inc (NYSE: AZTR).
NASDAQ: AZTR
AZTR Trading
-0.2% G/L:
$0.195 Last:
866,783 Volume:
$0.209 Open:
